Yes, unfortunately the technology did not work as well as PD-L1 inhibitors on a type of cancer that it should have had an advantage. With the great cervical data, I wonder why this does not work as well? Confusing. It may, however, work as a combo or adjuvant setting (from mypekeispooped post 47774). So any partner would probably go that angle. The 100% CR from the Brown study is still very impressive. How long has it been since the 11 were dosed? would be great to get an update and I bet they are fine given disease free diagnosis after ADXS treatment.
It took me 2 months to figure out the Phase II anal data and how to compare and analyze as a layman. It wasn't until Julius_Kelp posted the link below that I realized it wasn't comparatively good. The company should have explained these results but with as much as I have invested I should have been better at researching. The thing is, I believe most small investors didn't have a clue either (based on lots of comments from this board) until the 10K report.
FMR likely had some very diligent analysts with strong medical backgrounds that caught this right away and decided to bail especially with management turmoil. Adage was well prepared with short, long and warrants to go either way.
I don't like how the company does not explain results to investors but I suppose that is one angle to keep the stock from crashing fast. But, as I said, I prefer a one day 50% drop to a long postponed 3 month one.
News 
Market Data 
Discover 
